

1 DAVIS WRIGHT TREMAINE LLP
2 Jacob M. Harper (SBN 259463)
 jharper@dwt.com
3 Nicole S. Phillis (SBN 291266)
 nicolephillis@dwt.com
4 Heather F. Canner (SBN 292837)
 heathercanner@dwt.com
5 865 South Figueroa Street, Suite 2400
6 Los Angeles, California 90017-2566
7 Telephone: (213) 633-6800
8 Facsimile: (213) 633-6899

9 *Attorneys for Defendant*
10 *The Kroger Company*

11 **UNITED STATES DISTRICT COURT**
12 **SOUTHERN DISTRICT OF CALIFORNIA**

13 SHAVONDA HAWKINS, on behalf of
14 herself and all others similarly situated,

15 Plaintiff,

16 vs.

17 THE KROGER COMPANY,
18

19 Defendant.
20
21
22
23
24
25
26
27
28

Case No. 3:15-cv-2320-JM-AHG
Assigned to the Hon. Jeffrey T. Miller

**MEMORANDUM OF POINTS AND
AUTHORITIES IN SUPPORT OF
MOTION FOR SUMMARY
JUDGMENT OR, IN THE
ALTERNATIVE, MOTION FOR
PARTIAL SUMMARY JUDGMENT**

[DEF.'S MOTION 1 OF 3]

***[Notice of Motion; Omnibus
Declaration of Jacob M. Harper; and
Proposed Order Filed Concurrently]***

Date: June 15, 2020
Time: No oral arg. unless
requested by Court
Courtroom: 5D
Action Filed: October 15, 2015

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. RELEVANT BACKGROUND	4
A. Hawkins Uses Kroger Breadcrumbs From 2000 to 2015.	4
B. In 2005, Hawkins Ignores Doctor’s PHO “Red Flags.”	5
C. In 2008, “0g Trans Fat” First Appears on Kroger Label.....	6
D. In 2011–2013, Hawkins Ignores Warnings From Counsel.....	6
E. In 2012, Hawkins Sues in Other Mislabeling Actions.....	7
F. In 2015, Hawkins Stops Using Kroger Breadcrumbs.	7
G. In 2015, FDA and Congress Confirm Use of PHO Until 2018.	7
III. PROCEDURAL HISTORY	8
A. Hawkins Files This Action.	8
B. The Court Dismisses the Complaint Under Rule 12(b)(6).....	8
C. The Ninth Circuit Reverses and Remands for Discovery.	9
D. This Court Orders Discovery for an “Evidentiary Motion.”	9
E. Depositions and Discovery Take Place.	9
F. Kroger Opposes a Motion for Class Certification.....	9
G. Kroger Files This Motion and Its <i>Daubert</i> Motions.	9
IV. KROGER IS ENTITLED TO SUMMARY JUDGMENT.	9
A. Hawkins’s Testimony Conclusively Defeats Causation.	10
1. Causation Is an Affirmative Element of Each Claim.	10
2. The Purchase Timeline Fatally Undermines Causation.....	11
B. All Hawkins’s Claims Are Time Barred.	14
C. The Follow-On Class Claims Must Also Be Dismissed.	16

TABLE OF CONTENTS (cont'd)

	<u>Page</u>
V. ALTERNATIVE PARTIAL SUMMARY JUDGMENT IS MERITED.....	16
A. The Use Claims (COAs 1, 2) Fail As PHO Was Not Unlawful.	17
1. Collateral Estoppel Bars Relitigating PHO Legality.	17
2. On the Merits, the Claims Still Fail the “Unlawful” Prong.	18
3. The “Unfair” Claim Also Fails.	22
B. The Mislabeling Claims Fail (COAs 4–8).	23
C. The Warranty Claims Fail (COAs 3, 9).	25
D. Injunctive Relief Is Also Not Available.	25

TABLE OF AUTHORITIES**Page(s)****Cases**

<i>Backus v. Biscomerica Corp.</i> , 378 F. Supp. (N.D. Cal. 2019)	19, 20, 21, 22
<i>Backus v. Conagra Foods, Inc.</i> , 2016 WL 3844331 (N.D. Cal. July 15, 2016).....	20, 21
<i>Backus v. Gen. Mills</i> , 2018 WL 6460441 (N.D. Cal. Dec. 10, 2018).....	21
<i>Becerra v. Dr Pepper/Seven Up, Inc.</i> , 945 F.3d 1225 (9th Cir. 2019)	3, 23
<i>Cardinal Health 301 v. Tyco Elecs. Corp.</i> , 169 Cal. App. 4th 116 (2008)	25
<i>Celotex Corp. v. Catrett</i> , 477 U.S. 317 (1986).....	10
<i>Chow v. Neutrogena Corp.</i> , 2013 WL 5629777 (C.D. Cal. Jan. 22, 2013)	13
<i>Clark v. Hershey Co.</i> , 2019 WL 6050763 (N.D. Cal. Nov. 15, 2019)	10, 11, 13, 14
<i>Clemens v. DaimlerChrysler Corp.</i> , 534 F.3d 1017 (9th Cir. 2008)	3, 23
<i>Fox v. Ethicon Endo-Surgery, Inc.</i> , 35 Cal. 4th 797 (2005)	16
<i>Gunawan v. Howroyd-Wright Emp't Agency</i> , 997 F. Supp. 2d 1058 (C.D. Cal. 2014)	18
<i>Harshbarger v. Philip Morris, Inc.</i> , 2003 WL 23342396 (N.D. Cal. Apr. 1, 2003).....	15

TABLE OF AUTHORITIES (cont'd)**Page(s)****Cases**

<i>Hawkins v. AdvancePierre Foods, Inc.</i> , 2016 WL 6611099 (S.D. Cal Nov. 8, 2016)	<i>passim</i>
<i>Hawkins v. AdvancePierre Foods, Inc.</i> , 733 F. App'x 906 (9th Cir. 2018)	<i>passim</i>
<i>Hawkins v. Kellogg Co.</i> , 224 F. Supp. 3d 1002 (S.D. Cal. 2016)	21, 22
<i>Hawkins v. Kroger Co.</i> , 906 F.3d 763 (9th Cir. 2018)	1, 9, 25
<i>Hicks v. PGA Tour, Inc.</i> , 897 F.3d 1109 (9th Cir. 2018)	22
<i>Hodsdon v. Mars, Inc.</i> , 891 F.3d 857 (9th Cir. 2018)	18
<i>Johns v. Bayer Corp.</i> , 2013 WL 1498965 (S.D. Cal. Apr. 10, 2013)	24
<i>Jolly v. Eli Lilly & Co.</i> , 44 Cal.3d 1103 (1988)	14
<i>Khasin v. Hershey Co.</i> , 2014 WL 1779805 (N.D. Cal. May 5, 2014)	10, 13
<i>Kwikset Corp. v. Superior Court</i> , 51 Cal. 4th 310 (2011)	10
<i>Lierboe v. State Farm Mut. Auto. Ins. Co.</i> , 350 F.3d 1018 (9th Cir. 2003)	16
<i>Linde, LLC v. Valley Protein, LLC</i> , 2019 WL 3035551 (E.D. Cal. July 11, 2019)	22
<i>Matsushita Elec. Indus. Co. v. Zenith Radio Corp.</i> , 475 U.S. 574 (1986)	10

TABLE OF AUTHORITIES (cont'd)**Page(s)****Cases**

<i>McQuillion v. Schwarzenegger</i> , 369 F.3d 1091 (9th Cir. 2004)	18
<i>NBCUniversal Media, LLC v. Super. Court</i> , 225 Cal. App. 4th 1222 (2014)	15
<i>NorthBay Healthcare Grp.-Hosp. Div. v. Blue Shield of Cal. Life & Health Ins.</i> , 342 F. Supp. 3d 980 (N.D. Cal. Oct. 26, 2018)	22
<i>Ries v. Arizona Beverages USA LLC</i> , 287 F.R.D. 523 (N.D. Cal. 2012).....	14, 16
<i>Sateriale v. R.J. Reynolds Tobacco Co.</i> , 697 F.3d 777 (9th Cir. 2012)	11, 13
<i>Soliman v. Philip Morris, Inc.</i> , 311 F.3d 966 (9th Cir. 2002)	15
<i>Spacone v. Sanford, L.P.</i> , 2018 WL 4139057 (C.D. Cal. Aug. 9, 2018).....	13
<i>Victor v. R.C. Bigelow, Inc.</i> , 2016 WL 4502528 (N.D. Cal. Aug. 29, 2016)	24
<i>Wilson v. Frito-Lay N. Am., Inc.</i> , 260 F. Supp. 3d 1202 (N.D. Cal. 2017).....	10

Statutes

21 U.S.C.	
§ 342.....	<i>passim</i>
§ 342(a)(1).....	7, 20
§ 348.....	<i>passim</i>
§ 348(a)	7, 20
§ 348(c)(1)(A)	19

TABLE OF AUTHORITIES (cont'd)**Page(s)****Statutes (cont'd)**

California Business & Professions Code

§ 17200..... 17

§ 17208.....*passim*

California Civil Code

§ 1783.....*passim*

California Code of Civil Procedure

§ 338(a)*passim*

California Commercial Code

§ 2314(1) 25

§ 2316(3)(b) 25

§ 2725 14

California Health & Safety Code

§ 110100..... 17, 22

§ 110398..... 22

Consolidated Appropriations Act, 2016, Pub. L. No. 114-113, § 754,

129 Stat. 2242, 2284 (2015).....*passim***Rules**

Federal Rule of Civil Procedure

12(b)(6) 1, 8

30(b)(6) 6, 9

56(a) 9

Regulations

21 C.F.R.

§ 170.30..... 19

§ 170.30(c)(1)..... 19

§ 171.100..... 19

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

TABLE OF AUTHORITIES (cont'd)

Page(s)

Regulations (cont'd)

FDA, Final Determination Regarding PHOs

80 Fed. Reg. 34650 (June 17, 2015) 19

83 Fed. Reg. 23358 (May 21, 2018) 19

Other Authorities

H.R. Rep. No. 114-205 (2015) 21

MEMORANDUM OF POINTS AND AUTHORITIES

I. INTRODUCTION

In this action, the third lawsuit she has filed based on near-identical claims, plaintiff Shavonda Hawkins asserts that food she purchased for 15 years straight, two flavors of Kroger Breadcrumbs, improperly contained partially hydrogenated oil (PHO), a form of trans fat that, despite years of information from her doctors dating back to 2005, she didn't care about until her lawyers told her to 10 years later in 2015. She filed this lawsuit, claimed she was induced into purchasing the product by the product label "0g trans fat," and sought millions of dollars in class relief on a class basis. After the Ninth Circuit remanded from a dismissal on the pleadings because it found her allegations "could" state a theoretical basis for some claims, *Hawkins v. Kroger Co.*, 906 F.3d 763, 771 (9th Cir. 2018), it asked this Court to reassess Hawkins's claims following discovery.

What has discovery revealed? As expected, Hawkins's deposition and other discovery has confirmed what was apparent from the start of this case and in every other case she has brought: Hawkins is not a legitimate plaintiff, has suffered no injury caused by Kroger, has no evidentiary basis to support her claims, and no legal basis for others. She has no case. By this motion, Kroger seeks summary judgment of all claims or, in the alternative, partial summary judgement on particular theories she asserts.

Summary Judgment of All Claims. The Court should grant summary judgment on two independent post-deposition grounds, which will also moot her pending class certification and exclusion motions.

1. No Causation/Reliance. Discovery shows Hawkins did not actually rely on a label or suffer any real injury. To establish reliance and causation, Hawkins claims the statement "0g trans fat," as used on the front of Kroger breadcrumb labels since 2008, duped her into purchasing the products when, in fact, they contained trace amounts of PHO. In deposition, however, Hawkins repeatedly

revealed the “0g trans fat” label never impacted her buying habits (much less cause a purchase). To the contrary, she admitted she purchased Kroger breadcrumbs, consistently and without interruption, for 15 years—since 2000—6 times per year. She did so out of long-standing habit and preference because they were the best ingredient for her family favorite, “meatloaf.” Indeed, she testified she religiously bought Kroger breadcrumbs without regard to the label, as evidenced by testimony that: (a) her doctor annually warned her to look for “red flags” such as “partially hydrogenated oil” on ingredient labels, *yet continued her buying habit uninterrupted even though PHO was listed on Kroger breadcrumbs since at least 2005*; (b) her uninterrupted purchases continued without change through 2007, 2008, and 2009, even as the challenged label “0g trans fat” first appeared in 2008, *showing “0g trans fat” had no impact on her*; and (c) in 2011, after her lawyers invited her to become a plaintiff in several lawsuits—all involving trans fat—she continued purchasing at the same rate. ***Despite all that, she did not limit her purchases for another four years.*** She didn’t care about the label or PHO; she cared about the breadcrumbs’ taste, cost, and suitability for her meatloaf. That’s it.

2. Statute of Limitations. Further, Hawkins’s unexplainable delay in bringing suit requires dismissal on limitations grounds. She was on inquiry notice of the very “injury” she claims here—the possibility that foods she purchased, including Kroger breadcrumbs, may contain PHO—in ***2005, a full decade before bringing suit***, which she admits her physicians (and others) advised her to read the ingredient labels for “red flags” of PHO and trans fats. Her doctor made the same warning to read the ingredient declaration every year, including in 2008 when “0g trans fat” first appeared on the label. With inquiry notice dating to the mid-2000s, she should have filed no later than 2012.

Alternative Partial Summary Judgment. In the alternative, partial summary judgment as to each liability theory is appropriate.

1. Use Claims (COAs 1, 2). The First and Second Causes of Action for

violation of the Unfair Competition Law (UCL) unlawful and unfair prongs allege the use of PHO in Kroger Breadcrumbs until 2015 violated the Food and Drug Act, 21 U.S.C. §§ 342, 348, as well as Sherman Act provisions that incorporate those sections. But these claims fail because (a) they are barred by collateral estoppel, as Hawkins made and lost the exact same argument before Judge John Houston of this Court, which was affirmed by the Ninth Circuit in *Hawkins v. AdvancePierre Foods, Inc.*, No. 15-cv-2309-JAH (BLM), 2016 WL 6611099 (S.D. Cal.), *aff'd* 733 F. App'x 906, 906 (9th Cir. 2018); and (b) even reviewed independently, this Court will find PHO use was *not* unlawful through 2018, as a result of federal law and regulations, as many other cases in addition to *AdvancePierre* have ruled.

2. Mislabeling Claims (COAs 4–8). The Fourth through Eight Causes of Action allege violations of the UCL, False Advertising Law (FAL), and Consumers Legal Remedies Act (CLRA) on the basis that, under the well-established “reasonable consumer test,” the term “0g trans fat” is false or misleading. Here, Hawkins alleges a reasonable consumer would equate “0g trans fat” with “no trans fat whatsoever,” not even trace amounts. But under the reasonable consumer test, plaintiffs “must produce” actual “*evidence*”—surveys and other documentation, not allegations or speculation—“showing ‘a likelihood of confounding an appreciable number of reasonably prudent purchasers exercising ordinary care.’” *Clemens v. DaimlerChrysler Corp.*, 534 F.3d 1017, 1026 (9th Cir. 2008); *Becerra v. Dr Pepper/Seven Up, Inc.*, 945 F.3d 1225, 1228-29 (9th Cir. 2019). While settled law and industry practice require consumer surveys to test reasonable consumers’ understanding of specific statements, Hawkins provides nothing. Her sole “evidence” aside from her say-so is a stray half-sentence thought from an epidemiology expert, Nathan Wong, Ph.D—the subject of a concurrently filed *Daubert* motion—who admittedly has no marketing experience, no survey experience, and no reliable foundation for his testimony. With no evidence, she does not meet her burden for any of her mislabeling claims.

Hawkins was first made aware of possible issues regarding partially hydrogenated oils starting in 2005, when her doctor and television commercials identified “red flag[s]” about PHOs and trans fat. Ex. 1 at 45:2–51:3, 93:6–94:24. As Hawkins acknowledges, starting 2005, she was specifically informed about the importance of reading ingredient labels by her physician, whom she was required to visit annually:

[Counsel]: Were the TV commercials the first warning or the first information you saw regarding the dangers of trans fat?

[Hawkins]: Well, *I would say the first red flag was probably my own doctor just talking about it, like—as far as, like, dieting and stuff like that, “Stay away from this” and stuff like that.* But then more and more the commercials started to come on and were basically scaring everybody. [. . .]

[Question]: So just to be clear, it would have *been prior to 2013* that your doctor told you about the dangers of trans fat and the types of packaged foods to avoid, correct?

[Hawkins]: *Yes.*

[Counsel]: *Do you recall approximately how far prior to 2013 that would have been?*

[Hawkins]: I’d say maybe *2005*, ’6, ’7, ’8, ’9.

Ex. 1 at 45:23–46:7, 49:21–50:3 (emphasis added).²

“Partially hydrogenated oil” in was called out as an ingredient to search for:

[Counsel]: And partially hydrogenated oil is – that’s the ingredient that your doctor told you contained trans fat?

[Hawkins]: That trans fat can come from—come from that, yes. *So there is no way possible that—if it contains the PHO, there is no way possible that, if it contains that, that it will have 0 trans fat.*

Ex. 1 at 94:7–14 (emphasis added); *id.* at 94:15–24 (confirming the information about watching labels for PHO was from “different conversations over the years” beginning in 2005). During these visits from 2005 on, she was advised “*to look at*

² As a bus driver, Hawkins was required to pay particular attention to her physician’s warnings and have annual physicals. Ex. 1 at 19:2–6, 23:11–18.

1 *the nutritional-fact labeling and ingredients*” for partially hydrogenated oil. *Id.* at
2 50:23–51:3 (“Yeah, to [] try to pay attention as much as I could.”).

3 Despite these warnings, she admitted she *did not look at the ingredients*,
4 including the “partially hydrogenated oil” of which her physician and television
5 commercials made her specifically aware. *See, e.g., id.* at 97:19-21 (“Q: You
6 mentioned earlier that you didn’t always read the ingredients; is that right? A:
7 Yes.”); *id.* at 97:24–98:1 (“I may not have had time to sit and read every single
8 label”); *id.* at 98:7–8 (“I didn’t always have time to fully read the ingredient list.”).

9 **C. In 2008, “0g Trans Fat” First Appears on Kroger Label.**

10 Although Hawkins makes conclusory claims that the front label statement
11 “0g Trans Fat” induced her to purchase breadcrumbs (*e.g.*, Compl. ¶ 76; *see also*
12 Ex. 1 at 72:23–73:7), *the undisputed evidence shows, the statement “0g Trans*
13 *Fat” did not appear on the front label until 2008*. Kroger’s Package Design Team
14 Manager, Kim Bower (who was also deposed as a Rule 30(b)(6) witness) explained
15 Kroger breadcrumbs labels first contained the front label statement “0g Trans Fat”
16 in November 2008, some *eight years after* Hawkins began purchasing them
17 regularly. Ex. 3 (Bower Decl.) ¶¶ 8, 10 (“the statement ‘0g Trans Fat’ did not
18 appear on the front of the label for Kroger [Plain or Italian] Bread Crumbs in store
19 shelves until November 2008”) & Exs. A, B (Plain/Traditional Bread Crumbs and
20 Italian Breadcrumb labels, dated 2005, showing no “0g Trans Fat” claim on front)³;
21 *see* Ex. 2 (Bower Dep.) at 7:15–18. *Hawkins did not buy more with the new “0g*
22 *trans fat” label, but continued purchasing with the exact same six-time-per-year*
23 *frequency as she had done for a decade before*. Ex. 1 at 77:7–9, 99:19–100:2.

24 **D. In 2011–2013, Hawkins Ignores Warnings From Counsel.**

25 Hawkins admits she did not bother to “look at the ingredient list” until
26 sometime after “I had spoke [*sic*] to Mr. Weston,” meaning around 2011 or 2012—
27

28 ³ Kroger Plain Breadcrumbs were later renamed Traditional. Ex. 3 (Bower
Decl.) ¶ 8.

1 at least six years after her doctor first issued “red flags” in 2005. Ex. 1 at 93:10-
 2 94:3; *see also id.* at 40:16-22 (noting Hawkins first met counsel “in 2011 or ’12,
 3 somewhere in there”). Yet, even after her *counsel’s* warnings, she continued
 4 purchasing the products with the exact same six-time-per-year frequency as she had
 5 done for a decade before. *Id.* at 77:7–9, 99:19–100:2.

6 **E. In 2012, Hawkins Sues in Other Mislabeling Actions.**

7 During this period, Hawkins also revealed she was a plaintiff in at least three
 8 other mislabeling lawsuits, each time also represented by The Weston Firm.⁴ First
 9 filed in 2012, these cases concerned ingredient- and labeling-related claims similar
 10 to those here. *See* Harper Decl., Exs. 5–7 (complaints). They demonstrated a
 11 particular and specialized concern for product ingredients, but Hawkins continued
 12 to purchase the Kroger breadcrumbs without regard to the ingredients

13 **F. In 2015, Hawkins Stops Using Kroger Breadcrumbs.**

14 Three months before filing this lawsuit, Hawkins abruptly stops purchasing
 15 Kroger breadcrumbs in 2015. Compl. ¶¶ 71, 74; Ex. 1 at 100:3–12. She admits
 16 that, despite 15 years of breadcrumbs consumption, she did not suffer any of the
 17 litany of ailments she alleged trans fat causes in her complaint, or any other injury.
 18 Compl. ¶¶ 21, 24–60; Ex. 1 at 30:11–31:8; *see id.* at 27:23–30:10, 84:3–85:16.

19 **G. In 2015, FDA and Congress Confirm Use of PHO Until 2018.**

20 In December 2015, President Barack Obama signed into law the
 21 Consolidated Appropriations Act, 2016, Pub. L. No. 114-113, § 754, 129 Stat.
 22 2242, 2284 (2015) (CAA), which provided, among other things: “No partially
 23 hydrogenated oils as defined in the [Final Determination] shall be deemed unsafe
 24 within the meaning of [21 U.S.C. 348(a)] . . . and no food that . . . bears or contains
 25 a partially hydrogenated oil shall be deemed adulterated under [21 U.S.C. 342(a)(1)]
 26

27 ⁴ *See Hawkins v. Gerber Co.*, No. 12-cv-465-MMA (filed Feb. 23, 2012);
 28 *Hawkins v. AdvancePierre Foods*, No. 15-cv-2309-JAH (filed Oct. 14, 2015); and
Hawkins v. Kellogg Co., No. 16-cv-0147-JAH; Ex. 1 at 10:22-11:14, 123:3–124:18.

1 or (a)(2)(C)(i)] by virtue of bearing or containing a partially hydrogenated oil until
2 the compliance date as specified in such order (June 18, 2018).”

3 **III. PROCEDURAL HISTORY**

4 **A. Hawkins Files This Action.**

5 Two months before the CAA, Hawkins filed this lawsuit on October 15,
6 2015, invoking federal jurisdiction under CAFA and seeking nationwide class
7 relief. Compl. ¶¶ 1, 114. Hawkins sued Kroger in October 15, 2015 based on
8 Kroger’s purported mislabeling of its Bread Crumbs as containing “0g Trans Fat.”
9 Compl. ¶ 9. Hawkins alleged that, through 2015, this marketing of the Bread
10 Crumbs was false or misleading because they contain PHO, which contain trace
11 amounts of trans fat. *Id.* ¶ 3. Based on this allegation, Hawkins asserted claims for
12 violation of UCL, FAL, CLRA, and express and implied warranties. *Id.* ¶¶ 122-87.
13 Hawkins’s claims fall into two categories: (1) Kroger misleadingly advertises the
14 Bread Crumbs as containing “0g Trans Fat” on the front of the package when, in
15 fact, the product contains between 0g and 0.5g trans fat (the “Mislabeling Claims”);
16 and (2) there is no safe level of trans fat and that the product’s inclusion of PHOs
17 cause adverse health effects (the “Use Claims”). ECF No. 40 at 2.

18 As Hawkins admittedly did not suffer any injury from consuming Kroger
19 Breadcrumbs, Ex. 1 at 27:23–31:8, her sole damages theory is that she paid more
20 for the product than it is worth, and is therefore entitled to economic damages.

21 **B. The Court Dismisses the Complaint Under Rule 12(b)(6).**

22 In November 2015, Kroger filed a motion to dismiss under Federal Rule of
23 Civil Procedure 12(b)(6), citing a host of defects in Hawkins’s complaint, including
24 that her pleadings showed an apparent lack of reliance. Dkt. 11. This Court granted
25 the motion to dismiss on March 17, 2016 with prejudice, finding Hawkins failed to
26 plead sufficient facts for standing and finding some claims preempted. Dkt. 19.

27 **C. The Ninth Circuit Reverses and Remands for Discovery.**

28 Hawkins appealed the Court’s order dismissing the action, and on October 4,

2018, the Ninth Circuit reversed and remanded. 906 F.3d 763 (9th Cir. 2018). The Court applied then-new Ninth Circuit authority regarding pleading standards to find Hawkins’s reliance allegations acceptable at the pleading stage, and remanded for discovery, repeatedly noting reliance and other issues were better resolved as fact questions with the benefit of discovery. *Id.* at 768–69, 772.

D. This Court Orders Discovery for an “Evidentiary Motion.”

On remand, this Court issued an order declining to dismiss on the pleadings, noting that some pleadings arguments were a “close call” and thus “defer[red] ruling on [them] until the presentation of an evidentiary motion.” Dkt. 40 at 10.

E. Depositions and Discovery Take Place.

Following remand, the parties engaged in discovery and Hawkins sat for deposition on January 3, 2020, testifying as described. Harper Decl. ¶ 2, Ex. 1. Kroger also produced witnesses for a deposition pursuant to Federal Rule of Civil Procedure 30(b)(6), which took place February 26, 2020, outside Cincinnati, Ohio. Harper Decl. ¶ 3 & Ex. 2. On April 27 and 29, Kroger took depositions of Hawkins’s putative expert witnesses, Drs. Robert Bowen and Nathan Wong. *Id.* ¶¶ 14, 18. Hawkins waived the use of expert Beatrice Golomb for pre-trial filings. *Id.*

F. Kroger Opposes a Motion for Class Certification.

Meanwhile, Hawkins filed her Motion for Class Certification on January 21, 2020. Dkt. 89. Kroger opposed. Dkt. 117, 102-1–102-3. The motion is pending.

G. Kroger Files This Motion and Its *Daubert* Motions.

Following completion of discovery, Kroger filed this motion for summary judgment and its *Daubert* motions to exclude the testimony of Hawkins’s experts.

IV. KROGER IS ENTITLED TO SUMMARY JUDGMENT.

Summary judgment is appropriate if there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law. Fed. R. Civ. P. 56(a). Once the movant meets the initial burden, the nonmovant must “go beyond the pleadings and . . . designate specific facts showing there is a genuine

1 issue for trial.” *Celotex Corp. v. Catrett*, 477 U.S. 317, 323–24 (1986). The
 2 nonmovant’s evidence must be sufficient such that the record, taken as a whole,
 3 could support a rational trier of fact in finding for the nonmoving party on that
 4 issue. *Matsushita Elec. Indus. Co. v. Zenith Radio Corp.*, 475 U.S. 574, 587 (1986).

5 **A. Hawkins’s Testimony Conclusively Defeats Causation.**

6 Lack of causation defeats all Hawkins’s claims, including those under the
 7 UCL (COAs 1, 2, 4, 5, 6); the FAL (COA 7); the CLRA (COA 8); and warranty
 8 theories (COAs 3, 9). For all these claims, Hawkins maintains Kroger’s label
 9 induced her to purchase the products—namely, but for Kroger’s “0g trans fat”
 10 statement, she would not have purchased the product, and therefore would not have
 11 allegedly suffered under her two theories of liability: the mislabeling theory, that
 12 she lost money because of the label, and the use theory, that she suffered
 13 unspecified risk of injury because of her ingestion of trans fats. Compl. ¶ 107;
 14 *Hawkins*, 906 F.3d at 768–69. Because the evidence shows, in fact, that Kroger did
 15 not cause her supposed injuries, the claims fail.

16 **1. Causation Is an Affirmative Element of Each Claim.**

17 California’s consumer protection statutes impose an express requirement of
 18 “actual reliance,” *i.e.*, proof that the plaintiff “would not have bought the product
 19 but for the misrepresentation.” *Kwikset Corp. v. Superior Court*, 51 Cal. 4th 310,
 20 326-27, 330 (2011). “To prevail on their causes of action under UCL, FAL, and the
 21 CLRA, Plaintiffs must demonstrate that they actually relied on the challenged
 22 misrepresentations and suffered economic injury as a result of that
 23 reliance.” *Wilson v. Frito-Lay N. Am., Inc.*, 260 F. Supp. 3d 1202, 1208 (N.D. Cal.
 24 2017); *Khasin v. Hershey Co.*, 2014 WL 1779805, at *4 (N.D. Cal. May 5, 2014)
 25 (“actual reliance requirement applies to [] claims under all prongs of the UCL”); *see*
 26 *Clark v. Hershey Co.*, 2019 WL 6050763, at *2 (N.D. Cal. Nov. 15, 2019)
 27 (dismissing express and implied warranty claims for lack of reliance and causation).

28 Hawkins is “required to prove actual reliance on the allegedly deceptive or

misleading statements . . . and that the misrepresentation was an immediate cause of their injury-producing conduct.” *Sateriale v. R.J. Reynolds Tobacco Co.*, 697 F.3d 777, 793 (9th Cir. 2012); *Clark*, 2019 WL 6050763, at *2 (“[c]ausation is . . . a necessary element under California law”; “plaintiff must [show] she would not have bought the product but for the misrepresentation”).

2. The Purchase Timeline Fatally Undermines Causation.

Courts frequently scrutinize purchase histories to determine whether a plaintiff “actually relied” on the defendant’s label. *E.g.*, *Sateriale*, 697 F.3d at 793 (no reliance where plaintiff did not purchase any additional products *after* the alleged misrepresentation was made); *Clark*, 2019 WL 6050763, at *2 (granting summary judgment; depositions showed buying timeline inconsistent with reliance).

Here, Hawkins’s admissions in deposition revealed the label simply did not matter. Her purchases remained unchanged before, after, and regardless of the “0g trans fat” statement; she bought Kroger breadcrumbs with the exact same six-times-per-year frequency in 2015 as she did in 2008, 2005, and 2000.

To review: Beginning in 2000 (and continuing uninterrupted until 2015), Hawkins consistently bought Kroger Breadcrumbs six times per year, confirmed her “buying habits stayed the same, 2000 all the way up to 2015,” because the taste, convenience, price, and other qualities made them ideal for her “week[ly] . . . meatloaf,” and thus were a “regular staple on my grocery list.” Ex. 1 at 73:5–18, 74:3–5, 75:10–76:4 77:10–78:3, 99:19–100:2, 101:4–6. Hawkins was “satisfied with the bread crumbs” and never returned a carton for a refund. *Id.* at 101:6–4.

Contrary to her allegations (Compl. ¶ 76), neither the “0g Trans Fat” nor anything else on the breadcrumb label statement caused her to purchase breadcrumbs. For starters, “the statement ‘0g Trans Fat’ did not appear on the front of the label for [either flavor of breadcrumbs Hawkins purchased] in store shelves until November 2008.” Ex. 3 ¶¶ 8, 10 (describing “0g trans fat” first appearing in 2008, Exs. A, B [labels from 2005 showing no “0g trans fat” statement on front

label]); Ex. 2 (Bower Dep.) at 7:15–18. Yet, Hawkins testified that she began her regular purchases of Kroger breadcrumbs eight years earlier in 2000 (Ex. 1 at 73:5–18, 74:3–5), and admitted repeatedly that she did not increase or otherwise change her purchases of Kroger breadcrumbs after the “0g trans fat” statement appeared in 2008 (*e.g.*, *id.* at 99:19–100:2, confirming “buying habits stayed the same, 2000 all the way up to 2015” and she “didn’t buy more one year or less one year”; *accord id.* 76:17–21, 77:7–9). Thus:

- For the period before 2008, Hawkins could not have relied on the statement “0 Trans Fat” on the front label because *it simply did not exist*.
- For the period after 2008, Hawkins demonstrably *did not rely* on the label because her buying habits admittedly remained precisely the same as before 2008. Ex. 1 at 77:7–9, 99:19–100:2.

Hawkins’s admissions regarding the lack of purchase changes resulting from the “0g trans fat” statement alone conclusively demonstrate no reliance. Hawkins’s myriad other admissions, however, confirm not only a lack of reliance, but that she affirmatively did not care about the content of PHO.

Hawkins admitted, for example, that beginning as far back as 2005, during annual mandatory physical exams, her doctor repeatedly advised her to watch her diet for trans fats, and particularly for “red flags” such as “partially hydrogenated oil” in the ingredient lists on food packaging. Ex. 1 at 45:2–51:3, 93:6–94:24. “Partially hydrogenated oil” was clearly listed in the ingredient panel at that time and going forward (Ex. 3 at Exs. A, B), but Hawkins simply failed to look at ingredient statements despite physician warnings to review for PHO (Ex. 1 at 45:23–46:7, 49:21–51:3, 94:7–24, 97:19–98:8.) She admitted hearing similar information about “red flags” from TV commercials and elsewhere during that time, yet did not bother looking at the label itself. Ex. 1 at 45:2–51:3, 93:6–94:24.

Hawkins’s willful ignorance continued for many years, through 2011, at least six years after her doctor first issued “red flags” in 2005, when, after “I had spoke [*sic*] to Mr. Weston” about trans fats (Ex. 1 at 93:10–94:3; *see also id.* at 40:16–22—

1 and after beginning to serve as a professional plaintiff in at least three mislabeling
 2 lawsuits beginning in 2012 (*supra* at 7; Ex. 1. at 10:22–11:14; *id.* at 123:3–124:18;
 3 Exs. 5–7)—she continued purchasing the products with the exact same six-time-
 4 per-year frequency as she had done for a decade before. *Id.* at 77:7–9, 99:19–100:2.

5 Given the details of her 15-year purchase and use history, it is clear Kroger’s
 6 labeling and use of PHO ***simply did not matter*** to Hawkins—and therefore her
 7 claimed injuries are not “a result of” Kroger’s conduct. The *only* reason she
 8 purchased these products is that she wanted them, and her after-the-fact thoughts on
 9 why she may not have wanted them now do not establish reliance or causation.

10 Hawkins’s testimony forecloses any genuine issue of fact as to whether
 11 Kroger’s label caused any alleged injury. Under long settled law of California and
 12 Ninth Circuit, evidence that the plaintiff made the same purchasing decision
 13 irrespective of the challenged representation defeats a showing of injury. *See, e.g.,*
 14 *Clark*, 2019 WL 6050763, at *3 (granting summary judgment, where depositions
 15 revealed purchase timeline demonstrating plaintiffs bought product regardless of
 16 label); *see also Sateriale*, 697 F.3d at 793 (no reliance where plaintiff did not
 17 purchase any additional products after the alleged misrepresentation was made);
 18 *Khasin*, 2014 WL 1779805, at *4 (granting summary judgment).⁵

19 *Clark* is instructive. There, Judge William Alsup in the Northern District of
 20 California granted summary judgment after finding that the plaintiffs’ deposition
 21 testimony fatally undermined their allegations of reliance. 2019 WL 6050763, at
 22 *2–4. One plaintiff, like Hawkins, claimed the challenged statement misled her
 23 before the statement even appeared, leading Judge Alsup to find the alleged injury
 24

25
 26 ⁵ *See also Spacone v. Sanford, L.P.*, 2018 WL 4139057, at *8 (C.D. Cal. Aug. 9,
 27 2018) (denying class certification; “repeat purchasers” could not have suffered
 28 injury on the basis of the challenged misrepresentation); *Chow v. Neutrogena Corp.*,
 2013 WL 5629777, at *1–2 (C.D. Cal. Jan. 22, 2013) (same; “repeat purchasers” of
 the challenged product who were motivated by “mere favorability toward
 products,” as opposed to “reliance upon specific advertised benefits of the products
 in this case,” suffered no injury).

(purchase of the product) occurred “because of an initial misunderstanding when the label was not even present,” not because of the defendant’s label. *Id.* at *3–4. For another, the challenged label statement appeared, as with Hawkins, *after* the plaintiff established her purchase habits, leading the court to conclude “there is no indication from the facts that he looked at it or based any purchasing decisions off of it.” *Id.* at *9. Prior buying habits compelled the purchases, not labels.

So too here. Given the details about her uniquely consistent 15-year purchase habits, the lack of effect of the 2008 label change, the ignorance of the 2005 “red flags” from her doctor, the further lack of action after her 2011 encounters with layers, the problems for Hawkins’s causation theory are starkly more troubling than even in *Clark*. Hawkins is the poster child for how *not* to demonstrate reliance. No genuine dispute exists as to Hawkins’s lack of causation, and Hawkins’s claims should be dismissed on this ground alone.

B. All Hawkins’s Claims Are Time Barred.

Even if she met her burden to show causation, Hawkins fails to overcome the three- and four-year statute of limitations applicable to all her claims. Dkt. 59 at 35; Dkt. 86 at 5; Cal. Civ. Code § 1783 (CLRA); Cal. Prof. & Bus. Code § 17208 (UCL); Cal. Comm. Code § 2725 (warranty); Cal. Civ. Proc. Code § 338(a) (FAL).

The applicable statutes of limitations begins from the moment the plaintiff is aware of or should be aware of her purported injury. *See Jolly v. Eli Lilly & Co.*, 44 Cal.3d 1103, 1109 (1988) (the statute of limitations begins to run “when the plaintiff suspects or should suspect that her injury was caused by wrongdoing”). Thus, if a plaintiff knows at the moment of purchase that her product contains an ingredient that is the subject of her lawsuit, then she knows of her “injury” and the statute of limitations begins to run at the time of purchase. *Ries v. Arizona Beverages USA LLC*, 287 F.R.D. 523, 534 (N.D. Cal. 2012).

Under California’s “single injury” rule, once the cause of action first accrues for a purchaser, the limitations clock begins to run for all purchases made by her.

1 *See Harshbarger v. Philip Morris, Inc.*, 2003 WL 23342396, at *6–7 (N.D. Cal.
 2 Apr. 1, 2003). If a plaintiff is aware of a harm but continues purchases, those
 3 repeated purchases do not restart the applicable limitation period; rather, a
 4 plaintiff’s injury from ongoing use of a product “would constitute not a new breach,
 5 but rather additional harm.” *NBCUniversal Media, LLC v. Super. Court*, 225 Cal.
 6 App. 4th 1222, 1237 (2014); *see Soliman v. Philip Morris, Inc.*, 311 F.3d 966 (9th
 7 Cir. 2002) (claim accrued at time of plaintiff’s initial notification of injury, not with
 8 subsequent purchases). Thus, the claim “accrues” at the earliest point at which the
 9 plaintiff knew or should have known the claimed injury.

10 Here, the thrust of all Hawkins’s causes of action is that was injured by
 11 paying for the Kroger breadcrumbs that, in her view, were worthless because the
 12 contained trans fat, and therefore she injuriously spent money on these products that
 13 she claims she did not believe contained PHO. Compl. ¶¶ 76, 106–07. Thus, the
 14 limitations periods accrued when she knew or should have known that Kroger
 15 breadcrumbs contained PHO. But the timeline constructed from her admissions
 16 demonstrates her claims accrued as early as 2005—and no later than 2008.

17 First, Hawkins’s deposition shows she should have known about the content
 18 of partially hydrogenated oils since at least 2005. As noted, Hawkins first learned
 19 of what she deemed “red flag[s]” about PHO and trans fat from television
 20 commercials and information warning about overuse of trans fats. Ex. 1 at 45:2–
 21 51:3, 93:6–94:24. She was specifically informed to watch for “the PHO,” *id.* at
 22 94:7–24, and confirmed she was explicitly warned to “**to look at the nutritional-**
 23 **fact labeling and ingredients**” for those PHOs. *Id.* at 50:23–51:3 (emphasis
 24 added). And it is beyond material dispute that Kroger breadcrumb labels, by that
 25 time, already disclosed “partially hydrogenated oil” in the very ingredient panel
 26 highlighted by her doctor. Ex. 3 (Bower Decl.) ¶¶ 7, 9 & Exs. A, B. Given
 27 Hawkins was put on inquiry notice of PHO in Kroger breadcrumbs in 2005, her
 28 claims accrued that year and she should have brought a lawsuit, at latest, by 2009.

Second, if Hawkins construes her “injury” as resulting from the “0g trans fat” label, then the limitations period began no later than 2008, when that statement first appeared (Ex. 3 ¶¶ 8, 10)—all while Hawkins was still receiving her annual physicals and warnings about PHO and trans fats (Ex. 1 at 45:23–46:7, 49:21–50:3). Hawkins’s later purchases and consumption of the product after 2005, and any continued “harms,” are merely a continuation of her earlier claim.

While her complaint makes two conclusory allegations of “delayed discovery” (Compl. ¶¶ 111–12), her testimony regarding the “red flags” about PHO fatally undermine this attempt to move out accrual. *Fox v. Ethicon Endo-Surgery, Inc.*, 35 Cal. 4th 797, 807 (2005) (“A plaintiff has reason to discover a cause of action when he or she has reason at least to suspect a factual basis for its elements.”). Doctor’s warnings, TV commercials, instructions to look for “red flags” in the ingredients—Hawkins had all she needed to suspect a factual basis for claiming PHO was wrongfully labeled or included in 2005, and at the latest when the “0g trans fat” statement appeared in 2008. “[T]he statute runs once she is put on inquiry notice: when the circumstances would lead a reasonable person to suspect wrongdoing.” *Ries*, 287 F.R.D. at 534. “A plaintiff has reason to discover a cause of action when he or she has reason to at least suspect a factual basis for its elements.” *Id.* All Hawkins’s claims are time-barred.

C. The Follow-On Class Claims Must Also Be Dismissed.

Because all Hawkins’s claims should be dismissed, the class claims must also be dismissed. *See Lierboe v. State Farm Mut. Auto. Ins. Co.*, 350 F.3d 1018, 1022 (9th Cir. 2003) (if named plaintiff cannot establish relief for herself, she may not “seek relief on behalf of himself or any other member of the class”).

V. ALTERNATIVE PARTIAL SUMMARY JUDGMENT IS MERITED.

If, *arguendo*, the Court moved past the causation and limitations issues, Kroger would still be entitled to partial summary judgment on specific claims.

A. The Use Claims (COAs 1, 2) Fail As PHO Was Not Unlawful.

1 First, Hawkins's First and Second Causes of Action allege Kroger violated
 2 the UCL's "unlawful" and "unfair" prongs by including PHOs in Kroger
 3 Breadcrumbs until 2015, thereby allegedly violating the federal FDA and
 4 California's Sherman Act as UCL predicates. Not so.

5 **1. Collateral Estoppel Bars Relitigating PHO Legality.**

6 For starters, Hawkins's use-based arguments under the UCL are barred by
 7 collateral estoppel because Judge Houston of this Court already rejected them
 8 against Hawkins and her counsel, as the Ninth Circuit affirmed. *Hawkins v.*
 9 *AdvancePierre Foods, Inc.*, No. 15-cv-2309-JAH (BLM), 2016 WL 6611099, at
 10 *3–5 (S.D. Cal. Nov. 8, 2016), *aff'd* 733 F. App'x 906, 906 (9th Cir. 2018).

11 In *AdvancePierre*, Hawkins alleged the manufacturer of packaged
 12 sandwiches illegally used PHO in its sandwiches through 2016, and brought claims
 13 under the UCL unlawful and unfair prongs for allegedly illegal and unfair use of
 14 PHO. 2016 WL 6611099, at *1. The defendant moved to dismiss the UCL claims
 15 on the ground that federal law, under the FDA's Final Determination and the CAA,
 16 deemed PHO use not unlawful, and thereby precluded the claims. *Id.* at *3.
 17 Agreeing, Judge Houston found "the current use of PHO in food products does not
 18 violate federal law," and therefore cannot serve as a basis for UCL claims. *Id.* at
 19 *4–5. The Ninth Circuit affirmed, holding:

20 [H]er allegations do not establish the requisite "unlawful, unfair or
 21 fraudulent business act or practice." Cal. Bus. & Prof. Code § 17200. A
 22 claim under the "unlawful" prong requires a predicate violation of
 23 another law [citations], but federal law did not prohibit PHOs prior to
 24 June 18, 2018, see Consolidated Appropriations Act of 2016, Pub. L. No.
 25 114-113, § 754, 129 Stat. 2242, 2284 (2015). Hawkins's complaint also
 26 cited a provision of California's Sherman Act that adopted federal law,
 27 Cal. Health & Safety Code § 110100, but *AdvancePierre*'s use of PHOs
 28 did not violate this provision because it did not violate federal law.

AdvancePierre, 733 F. App'x at 906.

AdvancePierre is collateral estoppel over Hawkins's claims that the use of

PHO before 2018 created UCL violations, because: “(1) the issue at stake [is] identical to the one alleged in the prior litigation; (2) the issue [was] actually litigated [by the party against whom preclusion is asserted] in the prior litigation; and (3) the determination of the issue in the prior litigation [was] a critical and necessary part of the judgment in the earlier action.” *McQuillion v. Schwarzenegger*, 369 F.3d 1091, 1096 (9th Cir. 2004) (affirming dismissal based on collateral estoppel). **First**, the issue is identical: here and in *AdvancePierre*, Hawkins asserts the mere “use” of PHO in packaged foods before 2018 constitutes illegal conduct under the unlawful and unfair UCL prongs, but in both cases the FDA and CAA preclude that finding. **Second**, the issue was actually litigated—twice. The defendant food manufacturer clearly raised the issue, and Hawkins fought it hard. 2016 WL 6611099, at *2 (acknowledging court considered Hawkins’s additional “surreply” brief over the issue); and Hawkins lost the appeal, too. 733 F. App’x at 906. **Third**, the determination of the issue was critical and necessary to the judgment: it was a basis for dismissing the use-based UCL claims, and it was the primary basis for affirmance.

2. On the Merits, the Claims Still Fail the “Unlawful” Prong.

Even if the Court considers the argument (again), it still fails. As to Plaintiff’s unlawful UCL claims, where, as here, plaintiff fails to identify any predicate violation of law, summary judgment must be granted. *Hodsdon v. Mars, Inc.*, 891 F.3d 857, 865 (9th Cir. 2018) (affirming dismissal of UCL claim because no predicate legal violation); *Gunawan v. Howroyd-Wright Emp’t Agency*, 997 F. Supp. 2d 1058, 1070 (C.D. Cal. 2014) (granting summary judgment; “UCL claim [] stands or falls depending on the fate of the antecedent” statutory violations).

Hawkins predicates her use-based UCL claims on perceived violations of the Food and Drug Act, 21 U.S.C §§ 342, 348, as well as Sherman Act provisions that incorporate § 348. Compl. ¶ 132 (“Kroger’s conduct is ‘unlawful’ because it violates the [FDCA],” citing 21 U.S.C. §§ 348, 342). Hawkins bears the burden to

1 show the use of PHO was illegal under §§ 342 and 348 until 2015.

2 The Federal Food, Drug, and Cosmetic Act empowered the FDA to regulate
3 the conditions under which “food additives” may be used in food products. *See* 21
4 U.S.C. § 348(c)(1)(A); 21 C.F.R. § 171.100. Under this authority, the FDA
5 established an approval process by which food producers could scientifically
6 demonstrate their food additives are safe. 21 C.F.R. § 170.30. The FDA exempted
7 from this requirement certain substances that experience revealed were safe “based
8 on common use in food prior to January 1, 1958.” 21 C.F.R. § 170.30(c)(1). Food
9 additives satisfying either criterion are “generally recognized as safe,” or “GRAS,”
10 and may be used in food products. 80 Fed. Reg. 34650, 34652.

11 As of 2015, PHOs had long been deemed GRAS based on a history of use
12 before 1958. *Backus v. Biscomerica Corp.*, 378 F. Supp. 3d 849, 854–55 (N.D. Cal.
13 2019) (in 2015, “the FDA noted . . . [PHOs] had been generally regarded as safe
14 and used in food products for decades”) (citing FDA, Final Determination
15 Regarding PHOs, 80 Fed. Reg. 34650 at 34651 (June 17, 2015)). In June 2015, the
16 FDA issued a Final Determination Order acknowledging that although PHOs had
17 long been considered GRAS, “there is no longer a consensus among qualified
18 experts that partially hydrogenated oils . . . are generally recognized as safe (GRAS)
19 for any use in human food.” Ex. 8 at 34651. The Final Determination did not
20 conclude that PHOs are unsafe or immediately ban their use. *Id.* at 34654. Rather,
21 it announced that those in the food industry would have until June 18, 2018 (the
22 “compliance date”) to cease using PHO. *Id.* at 34653.⁶ “The compliance date will
23 have the additional benefit of minimizing market disruptions by providing industry
24 sufficient time to identify suitable replacement ingredients for PHOs, to exhaust
25 existing product inventories, and to reformulate and modify labeling.” *Id.* at 34669.
26 The Determination “has the force and effect of law.” *Id.* at 34657.

27
28 ⁶ The FDA extended compliance dates to 2021 to allow existing products “to
work their way through distribution.” 83 Fed. Reg. 23358, 23359 (May 21, 2018).

1 In setting the three-year compliance date, the FDA expressly permitted food
 2 companies to continue using PHOs, as they had done before, through June 2018.
 3 *See id.*; *Backus v. Conagra Foods, Inc.*, 2016 WL 3844331, at *3 (N.D. Cal. July
 4 15, 2016) (“[PHOs] were widely treated as GRAS . . . until very recently, and the
 5 FDA has permitted their continued use until 2018”; “[T]he FDA’s final decision not
 6 to prohibit the sale of products containing [PHOs] until 2018 indicates that it was
 7 not and is not unlawful under federal law to sell them before the compliance date.”).

8 Following the FDA’s Final Determination, Congress enacted law likewise
 9 deeming the use of PHO lawful through June 2018. In December 2015, President
 10 Obama signed into law the CAA, which confirmed the use of PHO in food products
 11 was lawful and could not render foods “adulterated” or “unsafe” until 2018:

12 ***No partially hydrogenated oils as defined in the [Final***
 13 ***Determination] shall be deemed unsafe within the meaning of [21***
 14 ***U.S.C. 348(a)] and no food that is introduced or delivered for***
 15 ***introduction into interstate commerce that bears or contains a partially***
 16 ***hydrogenated oil shall be deemed adulterated under [21 U.S.C.***
 17 ***342(a)(1) or (a)(2)(C)(i)] by virtue of bearing or containing a partially***
 18 ***hydrogenated oil until the compliance date as specified in such order***
 19 ***(June 18, 2018).***

20 Pub. L. No. 114-113, § 754, 129 Stat. 2242, 2284 (2015) (emphasis added)⁷; *see*
 21 *Biscomerica.*, 378 F. Supp. 3d at 852 (“[The CAA]—consistent with the FDA’s
 22 Final Determination—stated that PHO would not be considered unsafe or
 23 unadulterated under federal law until the June 18, 2018 compliance date.”).

24 Notably, these are the very statutes upon which Hawkins relies to support her use
 25 claims. *E.g.*, Compl. ¶ 132 (“Kroger’s conduct is ‘unlawful’ because it violates the
 26 [FDCA],” citing 21 U.S.C. §§ 348, 342).

27 While the statute alone establishes the use of PHO is lawful, the CAA’s
 28 legislative history further clarifies that it enumerated the compliance period to
 prevent “unnecessary litigation” surrounding the use of PHO. H.R. Rep. No. 114-

⁷ The CAA passed *after* briefing on the Motion to Dismiss. *See* Dkt. 11, 14, 15.

205, at 71 (2015); *see Hawkins v. Kellogg Co.*, 224 F. Supp. 3d 1002, 1012 (S.D. Cal. 2016) (“[The CAA] is a clear step by Congress to preclude parties [] from bringing suit against food manufacturers based on the use of PHO before the compliance date.”); *AdvancePierre*, 2016 WL 6611099, at *4 (same); *Backus v. Gen. Mills*, 2018 WL 6460441, at *4 (N.D. Cal. Dec. 10, 2018) (“Congress has been clear that no liability can arise for use of PHOs before [] June 18, 2018[.]”).

Together, the FDA’s Final Determination and the CAA stand as decisive federal authority permitting food distributors to continue using PHO and trans fat until at least 2018, and rendering that conduct lawful until that time. *Biscomerica*, 378 F. Supp. 3d at 856 (“The FDA and Congress [] declared in a rulemaking and in legislation that foods containing PHO would not be deemed unsafe or adulterated until June 2018.”); *see id.* at 854–55 (“Congress was clear [in the CAA] that the use of PHO was not prohibited until 2018[.]”); *Gen. Mills*, 2018 WL 6460441, at *6 (“[The CAA] is clear and the use of PHOs in food before June 2018, the entirety of the time period covered by the complaint, is not unlawful.”).

In the wake of this unequivocal authority deeming the use of PHO lawful through 2018, the Ninth Circuit and various district courts in this circuit have dismissed both unlawful and unfair UCL claims—identical to those here—premised on the use of PHO in food. *E.g.*, *AdvancePierre*, 733 F. App’x at 906 (dismissing UCL claims premised on use of PHO); *Kellogg Co.*, 224 F. Supp. 3d at 1012 (same); *Conagra*, 2016 WL 3844331, at *3 (same); *Biscomerica*, 378 F. Supp. 3d at 854 (same). Indeed, “[t]he UCL cannot [] be used to proscribe otherwise permitted conduct.” *Id.* The Court should grant summary judgment as to the claims here, too.

As noted, Hawkins premises her claims on both federal and state law. Compl. ¶¶ 132–33. As to federal law, both Congress and the FDA have made clear that Kroger’s use of PHO from 2010 through 2015 was lawful under the very federal statutes Hawkins cites—21 U.S.C. §§ 348, 342—and therefore cannot serve as the predicate for an unlawful UCL claim. *AdvancePierre*, 733 F. App’x at 906

(no UCL claim because no predicate violation of federal law); *Kellogg*, 224 F. Supp. 3d at 1012 (same); *Biscomerica*, 378 F. Supp. 3d at 855 (same).

The UCL claims premised on violations of the California Sherman Law likewise fail. *See* Compl. ¶ 133 (citing the Sherman Law, Cal. Health & Safety Code §§ 110100, 110398). In fact, the Sherman Law simply adopts the very FDA regulations that permit the use of PHO, as Hawkins admits. Compl. ¶ 133 (“[Cal. Health & Safety Code] § 110100 [] adopts all FDA regulations a state regulations”). Because the use of PHO is lawful under the FDA regulations, it is equally lawful under California’s Sherman Law. *AdvancePierre*, 733 F. App’x at 906 (“Hawkins’s complaint also cited a provision of California’s Sherman Act that adopted federal law, Cal. Health & Safety Code § 110100, but [Defendant’s] use of PHOs did not violate this provision because it did not violate federal law.”); *Biscomerica Corp.*, 378 F. Supp. 3d at 855–56 (same, as to Cal. Health & Safety Code §§ 110100, 110398). The unlawful UCL claims therefore fail as a matter of law.

3. The “Unfair” Claim Also Fails.

As to Hawkins’s unfair claim, where, as here, the unfair UCL claim “overlaps entirely with the business practices addressed” in the plaintiff’s unlawful UCL claim, and the latter fails, the unfair UCL claim “cannot survive.” *NorthBay Healthcare Grp.-Hosp. Div. v. Blue Shield of Cal. Life & Health Ins.*, 342 F. Supp. 3d 980, 989 (N.D. Cal. Oct. 26, 2018) (granting summary judgment; “[plaintiff]’s claim under the ‘unfair’ prong overlaps entirely with the ‘unlawful’ prong and therefore cannot survive if . . . the unlawful prong does not survive”); *accord Hicks v. PGA Tour, Inc.*, 897 F.3d 1109, 1123–24 (9th Cir. 2018) (court’s “determination that the conduct” does not violate antitrust law “necessarily implies that the conduct is not ‘unfair’ toward consumers”); *Linde, LLC v. Valley Protein, LLC*, 2019 WL 3035551, at *21 (E.D. Cal. July 11, 2019) (granting summary judgment as to unfair UCL claim that overlapped with failed unlawful UCL claim); *see also AdvancePierre*, 733 F. App’x at 906 (affirming dismissal of unfair UCL claim

1 based on the use of PHO, because Hawkins “cannot satisfy” the tests).

2 **B. The Mislabeling Claims Fail (COAs 4–8).**

3 For her four mislabeling causes of action—the Fourth, Fifth and Sixth Causes
4 of Action under the UCL; the Seventh Cause of Action under the FAL, and the
5 Eighth Cause of Action under the CLRA—Hawkins alleges the phrase “0g trans
6 fat” was misleading to a reasonable consumer because Kroger breadcrumbs
7 contained trace levels of PHO, as disclosed on the ingredient panel. But Hawkins
8 does not meet her evidentiary burden under the reasonable consumer test.

9 “[C]laims under California’s consumer-protection statutes are governed by
10 the ‘reasonable consumer’ test.” *Becerra*, 945 F.3d at 1228-29 (applying standard
11 to UCL, FAL, and CLRA claims). “Under this standard, [the plaintiff] must ‘show
12 that members of the public are likely to be deceived.’” *Id.* “This requires more
13 than a mere possibility that [the product’s] label ‘might conceivably be
14 misunderstood by some few consumers viewing it in an unreasonable
15 manner.’” *Id.* “Rather, the reasonable consumer standard requires a probability
16 ‘that a significant portion of the general consuming public or of targeted consumers,
17 acting reasonably in the circumstances, could be misled.’” *Id.*

18 To meet this burden at the post-pleading, pre-trial stage summary judgment
19 stage, plaintiffs “must produce” actual “*evidence* showing ‘a likelihood of
20 confounding an appreciable number of reasonably prudent purchasers exercising
21 ordinary care.’” *Clemens*, 534 F.3d at 1026 (emphasis added). Thus, plaintiffs
22 must offer “[s]urveys and expert testimony regarding consumer assumptions and
23 expectations” to show a significant portion of the general consuming public or of
24 targeted customers could have been misled by the statement. *Id.*

25 Unlike at the pleading stage, allegations, anecdotal statements, or speculation
26 do not suffice. *E.g.*, *Victor v. R.C. Bigelow, Inc.*, 2016 WL 4502528, at *4 (N.D.
27 Cal. Aug. 29, 2016) (granting summary judgment; even if named plaintiff’s
28 “testimony suggests that he was misled, individual testimony is insufficient to

1 establish that a reasonable consumer is likely to be misled, as required under the
 2 reasonable consumer test”); *Johns v. Bayer Corp.*, 2013 WL 1498965, at *27–28
 3 (S.D. Cal. Apr. 10, 2013) (granting summary judgment; “Plaintiffs must prove that
 4 the representations at issue were ‘material’ to a reasonable consumer” but expert
 5 testimony not competent to do so).

6 Besides bare allegations, Hawkins has no evidence regarding the impact of
 7 Kroger’s label on a reasonable consumer at all, much less whether a reasonable
 8 consumer would interpret “0g trans fat” in the sweeping manner Hawkins claims.

9 As to Hawkins’s “experts,” they have nothing to add to the analysis relating
 10 to consumer deception. **Robert Bowen, Ph.D.**, an accounting professor with no
 11 opinions or expertise regarding consumer behavior, offers calculations for
 12 restitution (and are subject to a separate *Daubert* motion). His opinions admittedly
 13 have nothing to do with the “0g trans fat” statement, he offers no consumer survey,
 14 and he has nothing to do with the reasonable consumer test. Ex. 12; Ex. 13 (Bowen
 15 Dep.) at 30:4-20, 45:10-18, 54:1-56:20, 57:13-25. **Nathan Wong, Ph.D.**, an
 16 epidemiologist, includes one statement that: “I . . . believe, as a matter of accurate
 17 labeling, that the ‘0g Trans Fat’ claim in large type on the front of Kroger Bread
 18 Crumbs was misleading.” Ex. 15 (Wong Report) ¶ 29. But as detailed in the
 19 accompanying motion to exclude Dr. Wong’s testimony, (a) he is not qualified to
 20 opine on consumer behavior; (b) his statement is not evidence of an ultimate issue
 21 of law (whether a statement is “misleading”; and (c) his opinion is unsupported and
 22 unreliable. Mot. to Exclude at 5–23.

23 As explained in Kroger’s rebuttal expert report submitted by Dr. Bruce
 24 Isaacson—a qualified marketing expert—there is no “evidence” suggested or
 25 referenced anywhere by Hawkins to support the assertion that Kroger’s Bread
 26 Crumbs were “misleading[ly]” labeled. *See* Ex. 9 (Isaacson Rpt.) ¶¶ 4, 23, 38–39.
 27 The support typically required to prove consumer deception are controlled and well-
 28 designed “consumer surveys” that empirically test the effect of labels on consumers

1 and whether a statement is material reasonable consumers' purchase decision. *Id.*
 2 ¶¶ 24–38. Without testing, “we cannot know what messages the ‘0g Trans Fat’
 3 claim communicated to consumers, or whether consumers would have changed
 4 their purchase behavior if this claim had not appeared on packages[.]” *Id.* ¶ 39.
 5 Without a qualified expert or competent survey, Hawkins has no evidence showing
 6 that, as she must, a reasonable consumer would interpret “0g trans fat” on the front
 7 label to mean no trans fat whatsoever.

8 On summary judgment, the question is whether the plaintiff has *evidence* to
 9 back up those allegations; Hawkins may not rely on the pleading standards that “a
 10 consumer reading the label *could be misled* into believing that the product was free
 11 of trans fat.” 906 F.3d at 771. Because Hawkins fails provide reasonable consumer
 12 evidence, summary judgment is appropriate.

13 **C. The Warranty Claims Fail (COAs 3, 9).**

14 Last, the remaining claims—the Third and Ninth Causes of Action for breach
 15 of express and implied warranties—fail. *First*, Hawkins has also failed to state a
 16 claim breach of the implied warranty of merchantability. *See* Cal. Com. Code
 17 § 2314(1). Her allegation that she is too “busy” to read ingredients in the food she
 18 purchases does not excuse her failure to examine the labels. *See id.* § 2316(3)(b).
 19 *Second*, in her 15 year purchase history, Hawkins failed to provide reasonable
 20 notice, or any notice, of the alleged defects before filing suit. *E.g., Cardinal Health*
 21 *301 v. Tyco Elecs. Corp.*, 169 Cal. App. 4th 116, 136 (2008) (failure to provide
 22 notice two years after it acquired warranted action insufficient); Ex. 1 at 101:3–6.

23 **D. Injunctive Relief Is Also Not Available.**

24 Hawkins abandoned injunctive relief. Dkt. 36 at 25.

25 DATED: May 18, 2020

DAVIS WRIGHT TREMAINE LLP

By: /s/ Jacob M. Harper

Jacob M. Harper

Attorneys for Defendant

The Kroger Company

CERTIFICATE OF SERVICE

Shavonda Hawkins v. The Kroger Company

U.S.D.C. Southern District of California Case No. 3:15-cv-2320-JM-BLM

I the undersigned, declare:

At the time of service, I was over 18 years of age and not a party to this action. I am employed in the County of Los Angeles, State of California. My business address is 865 S. Figueroa Street, Suite 2400, Los Angeles, CA 90017.

On May 18, 2020, I served true copies of the following documents described as:

**MEMORANDUM OF POINTS AND AUTHORITIES IN SUPPORT OF
MOTION FOR SUMMARY JUDGMENT OR, IN THE ALTERNATIVE,
MOTION FOR PARTIAL SUMMARY JUDGMENT**

on the interested parties in this action as follows:

BY CM/ECF NOTICE OF ELECTRONIC FILING: I electronically filed the documents with the Clerk of the Court by using the CM/ECF system. Participants in the case who are registered CM/ECF users will be served by the CM/ECF system. Participants in the case who are not registered CM/ECF users will be served by mail or by other means permitted by the court rules.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct and that I am employed in the office of a member of the bar of this Court at whose direction the service was made.

Executed on May 18, 2020, at Los Angeles, California.

/s/ Jacob M. Harper

Jacob M. Harper